High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk.
High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk.
复制标题
DOI：
10.1016/j.bbacli.2015.01.005
复制
发表时间：
2015-06
期刊：
影响因子：
--
通讯作者：
Genest J
中科院分区：
文献类型：
--
作者：
Hafiane A;Genest J
血浆高密度脂蛋白胆固醇（HDL）包括脂蛋白种类的异质家族，其在表面电荷、大小以及脂质和蛋白质组成方面不同。虽然HDL胆固醇（C）质量是心血管风险的一种强有力的、分级的和连贯的生物标志物，但遗传和临床试验数据表明，HDL-C的简单测量可能不是预防动脉粥样硬化的原因，也不能反映HDL功能。事实上，HDL-C的测量可能是心血管健康的生物标志物。为了评估HDL功能作为潜在治疗靶点的问题，需要稳健且简单的分析方法。HDL复杂的多效性效应使得单一测量的开发具有挑战性。准确的HDL功能的实验室测定的发展必须被开发、验证并达到临床目的的高通量。本文综述了目前实验室技术的局限性，分离和量化HDL的方法和潜在的应用，以预测心血管疾病，强调在临床实践中作为潜在的生物标志物的紧急方法。
Plasma high density lipoprotein cholesterol (HDL) comprises a heterogeneous family of lipoprotein species, differing in surface charge, size and lipid and protein compositions. While HDL cholesterol (C) mass is a strong, graded and coherent biomarker of cardiovascular risk, genetic and clinical trial data suggest that the simple measurement of HDL-C may not be causal in preventing atherosclerosis nor reflect HDL functionality. Indeed, the measurement of HDL-C may be a biomarker of cardiovascular health. To assess the issue of HDL function as a potential therapeutic target, robust and simple analytical methods are required. The complex pleiotropic effects of HDL make the development of a single measurement challenging. Development of laboratory assays that accurately HDL function must be developed validated and brought to high-throughput for clinical purposes. This review discusses the limitations of current laboratory technologies for methods that separate and quantify HDL and potential application to predict CVD, with an emphasis on emergent approaches as potential biomarkers in clinical practice.